The Gulf Journal of Oncology
|
|
- Melissa Clark
- 5 years ago
- Views:
Transcription
1
2 The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery and Modified Radical Mastectomy E.F. Al Saeed, A.J. Al Ghabbban, M.A. Tunio A statistical quantification of radiobiological metrics in Intensity Modulated Radiation Therapy evaluation A. Surega, J. Punitha, S. Sajitha, BS Ramesh, A. Pichandi, P. Sasikala A method for assessment of radiation treatment chain of cervical cancer with combined external and brachy radiation therapy A. Chaparian, P. Shokrani Role of Lymphadenectomy and Its Impact On Survival In Endometrial Carcinoma An Institutional Experience S. Suchetha, P. Rema, S. Vikram, P.S. George, I. Ahmed Breast Cancer Epidemiology, Risk Factors and Tumor Profiles in Bangladeshi underprivileged women M. Rahman, A. Ahsan, F. Begum, K. Rahman Early hematological effects of chemo-radiation therapy in cancer patients and their pattern of recovery- A prospective single institution study H.N. Lee, M.K. Mahajan, S. Das, P. Jeyaraj, J. Sachdeva, M.S. Tiwana Platinum-based chemotherapy in metastatic triple negative breast cancer: Experience of a tertiary referral centre in India V.V. Maka, H. Panchal, S.N. Shukla, S.S. Talati, P.M. Sha, K.M. Patel, A.S. Anand, S.A. Shah, A.A. Patel, S. Parikh A Single Institution 18-Years Retrospective Analysis of Malignant Melanoma A. Mukherji, A.K. Rathi, P.K. Mohanta, K. Singh MRI and ultrasonography for assessing multifocal disease and tumor size in breast cancer: Comparison with histopathological results V. Rudat, A. Nour, N. Almuraikhi, I. Ghoniemy, I. Brune-Erber, N. Almasri, T. El-Maghraby Patient s Compliance On the Use of Extended Low Molecular Weight Heparin Post Major Pelvic Surgeries in Cancer Patients at King Hussein Cancer Center M. Baba, M. Al Masri, M. Salhab, M. El Ghanem Can we use Sorafenib for advanced Hepatocellular Carcinoma (HCC) Child Pugh B? K. Rasul, A. Elessam, S. Elazzazi, R. Ghasoub, A. Gulied Case Reports The external auditory canal as an unusual site for metastasis of breast carcinoma: A case report B.A. Baraka, B.J. Al Bahrani, S.S. Al Kharusi, I. Mehdi, A.M. Nada, N.H. Al Rahabi Primary Mixed Cellularity Classical Hodgkin lymphoma of the Lumbar spine An unusual presentation K.R. Anila, R. A. Nair, S. Prem, K. Ramachandran Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate J. Feki, G. Marrekchi, T. Boudawara, N. Rekik, S. Maatoug, Z. Boudawara, M. Frikha Conference Highlights /Scientific Contribution Workshop Highlights The Second Regional Training Of The Trainers (TOT) Workshop On Palliative Care, Kuwait, November News Notes Advertisements Scientific events in the GCC and the Arab World for the 1 st Semester of
3 Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery and Modified Radical Mastectomy E. F. Al Saeed 1, A. J. Al Ghabbban 1, M. A. Tunio 2 1 King Saud University, Riyadh, Saudi Arabia 2 King Fahad Medical City, Riyadh, Saudi Arabia Abstract Obesity and increased body mass index (BMI) are increasing among Saudi women across all age groups with an overall prevalence of 44%. Increased BMI is associated with advanced stage breast cancer and dismal survival; however impact of BMI on locoregional control (LRC) is less studied. We aimed to evaluate the impact of BMI on LRC in Saudi patients with breast cancer after breast conserving surgery (BCS) and modified radical mastectomy (MRM). Materials and methods: Between February 1988 and August 2008, 112 patients with breast cancer were treated with BCS and MRM followed by adjuvant chemotherapy and radiotherapy. Median age was years (23-76). Mean BMI was 38.1 kg/m 2 ( ); BMI < 18.5 kg/m 2 (underweight) in 1 (0.9%), BMI kg/m 2 (normal weight) in 19 (16.9%), BMI kg/ m2 (overweight) in 32 (28.6%), BMI kg/ m2 (obese) in 48 (42.9%) and BMI > 40 kg/m 2 (morbid obese) in 12 (10.7%). Median follow Introduction Obesity and overweight (body mass index >26 kg.m 2 ) are increasing among both sexes and across all age groups in the Kingdom of Saudi Arabia with an overall prevalence of 44% in Saudi women (1). Obesity is known as the major factor for development of breast cancer which is the most common malignancy in Saudi Arabia accounting for 26% of all newly diagnosed breast Corresponding Author: Mutahir A. Tunio, MBBS, FCPS (Radiation Oncology), Assistant Consultant, Radiation Oncology, King Fahad Medical City, Riyadh, Saudi Arabia. Tel: , Fax: drmutahirtonio@hotmail.com 7 up period was 9 years (5-17). Cox proportional hazard analysis was done using SPSS Results: A total of ten locoregional recurrences (8.93%) were seen. The 5 and 10 years LRC were 86.4% and 86.4% respectively. Multivariate analysis showed poor LRC in BMI <18.5 kg/m 2 (HR: 4.2; 95% CI , p 0.001) and kg/m 2 (HR: 3.4; 95% CI , p 0.01). Others factors associated with poor LRC were: age less than 40 years, premenopausal status, and no adjuvant radiotherapy, and T4, N2 and N3 stages. Conclusion: Underweight patients with breast cancer are more prone for locoregional recurrences as compared to obese and morbid obese patients. Key words: Body mass index, breast cancer, breast conserving surgery, modified radical mastectomy cancers in Saudi women and with incidence of 21.6 per 100,000 (2). Some studies have revealed a clear positive association between increased body mass index (BMI) and risk of developing breast cancer by 30-50% (3, 4). Elevated BMI has been shown to be associated with a poorer prognosis in breast cancer patients regardless of the menopausal status and increased mortality from other obesity-driven health problems (5), but retrospective data failed to show any impact of BMI on post treatment locoregional recurrence (LRR) in breast cancer patients (6,7,8). Recently, results from a French trial have shown that breast cancer patients with
4 Impact of BMI on Locoregional Control in Breast Cancer, E.F. Al Saeed, et. al. low BMI are at high risk of LRR after breast conserving surgery (BCS) followed by adjuvant chemotherapy and radiotherapy (9). However no data addressing direct impact on BMI on LRR in breast cancer patients after modified radical mastectomy (MRM) is available. The purpose of this study was to evaluate the impact BMI on LRR in Saudi patients with breast cancer treated with BCS or MRM followed by adjuvant hormonal, chemotherapy and adjuvant radiotherapy. Materials and Methods After approval from the Institutional Ethical Review Board (IRB) committee, records of 112 patients with breast cancer treated between February 1988 and August 2008 with BCS and MRM followed by adjuvant chemotherapy and radiotherapy were reviewed and comprised the study population. Inclusion criteria were (a) histopathological confirmed breast cancer, (b) T1-T4, N0-N2, (c) underwent BCS or MRM +/- adjuvant hormonal, chemotherapy and radiotherapy. Exclusion criteria were (a) presence of distant metastasis, (b) neoadjuvant chemotherapy and (c) inflammatory or inoperable tumors. BMI calculation Each patient was categorized according to BMI. Height and weight were measured at the time of surgery using institutional protocols and BMI was calculated using the formula of weight in kilograms divided by the square of the height in meters (kg/m 2 ). BMI was then categorized into five groups as follows: underweight as BMI < 18.5 kg/m 2 ; normal weight as BMI from 18.5 to 25 kg/m 2 ; overweight as BMI from 25 to 30 kg/m 2 ; obese as BMI from 31 to 40 kg/m 2 and morbid obese as BMI above 40 kg/m 2. Clinical and histologic variables likely to influence the risk of LRR studied were the following: Clinical variables Age, menopausal status, associated comorbidities, BMI groups, initial tumor size on physical, mammography and sonography 8 examination, laterality and location of primary tumor. Surgery was performed either wide local excision or MRM with axillary lymph node dissection. Adjuvant chemotherapy or hormonal therapy was given 4-5 weeks after surgery followed by radiotherapy. Histopathological variables Histopathological types of tumors according to WHO 1981 classification of breast tumors, grade according to Scarff Bloom and Richardson classification, pathological size of tumor, presence/absence of estrogen receptors (ER), progesterone receptors (PR), Her 2 neu overexpression, number of retrieved axillary lymph nodes and number of positive nodes, nodal density, presence of lymphovascular space invasion (LVSI) and margin status (negative or positive). Statistical analysis The primary endpoints were LRR and locoregional control (LRC). Secondary endpoints were disease free survival (DFS) and overall survival (OS). The time period from last follow up evaluation, appearance of local relapse and death were calculated from date of starting treatment. LRR was defined as any recurrence of tumor within the treated breast, chest wall or ipsilateral axilla and overlying skin. Skin recurrence was considered as local failure when located exclusively in ipsilateral breast or chest wall. Local recurrences occurring synchronously with distant metastasis were also included. DFS was defined as the duration between the entry date and the date of documented disease reappearance, death from cancer and/or last follow-up (censored). OS was defined as the duration between the entry date and the date of patient death or last follow-up (censored). Probabilities of LRC and DMC, DFS and OS were determined with the Kaplan-Meier method. The comparisons for various endpoints were performed using log rank test and Cox regression analysis. Univariate and multivariate analyses were also performed for different prognostic factors for LRR. All statistical analyses were performed using the computer program SPSS version 19.0.
5 Results G. J. O. Issue 17, 2015 Median follow up period was 9 years (range: 5-17). Patients characteristics according to BMI subgroups are shown in Table 1. 9
6 Impact of BMI on Locoregional Control in Breast Cancer, E.F. Al Saeed, et. al. Table 1: Patients characteristics according to body mass index groups Abbreviations: DM= diabetes mellitus, HTN= hypertension, HL= hyperlipidemia, T=Tumor, N=Nodes, IDC=infiltrating ductal carcinoma, ILC= invasive lobular carcinoma, LVSI= lymphovascular space invasion, ER= Estrogen receptors, PR= Progesterone receptors, BCS= breast conservation surgery, MRM=modified radical mastectomy Clinical characteristics Mean age of cohort was 47.0 years (range: 23-76; standard deviation (SD) 10.3). According to menopausal status, 93 patients (83.0%) were premenopausal and 19 patients (17.0%) were postmenopausal. Mean BMI was 31.8 kg/m2 (range: ;SD7.2). According to comorbidities, 72 patients (64.3%) have no comorbidities. Common morbidities in 40 patients (35.7%) were: hypertension in 14 patients (12.5%), diabetes in 9 patients (8.0%) and combined hypertension and diabetes in 6 patients (5.4%). Family history was positive in 17 patients (15.2%). In four patients (3.6%) there were bilateral breast cancer at the time of diagnosis. Majority of cohort (57 patients; %) had left side breast cancer and outer lower quadrant was common site of tumor location (50 patients; 45.9%) followed by upper outer quadrant (30 patients; 27.5%). Mean mammography size of tumor was 3.9 cm (range: 1-7;SD 2.3). Mean baseline CA15.3 level was 31.1 units/ml (range: ;SD 23.9) Histopathological characteristics Mean pathological tumor size was 3.4 cm (range: 1-10; SD 2.4) and infiltrating ductal carcinoma (IDC) was predominant histopathological variant seen in 95 patients (88.0%). Majority of tumors were moderately differentiated of grade 2 (68 patients;60.7%). According to marginal status, 77 patients (68.8%)
7 had negative margins. Majority of cohort was ER and PR positive (65 patients;58.0%) and Her 2 neu overexpression was seen in 10 patients (8.9%). Treatment characteristics Majority of patients had MRM (77 patients;71.3%) followed by BCS in 31 patients (28.7%). Mean axillary retrieved lymph nodes were 14.1 (2-42) after axillary dissection and sentinel node dissection. A total of 70 patients (62.5%) received adjuvant chemotherapy which was given within 5-6 weeks (range:3-11) of surgery. Adjuvant chemotherapy protocols were: CMF (18.6%), AC followed Paclitaxal (32.9%), FAC (32.9%), TAC (5.9%), AT (5.7%), FAC+TAC (4%). A total of 89 patients (83.0%) received local radiation therapy which was started 22 weeks (18-26) after the surgery and 3-5 weeks after the completion of chemotherapy. For BCS patients, whole breast radiation therapy was delivered in 2Gy fractions to mean total mean dose of 50 Gy (45-64) and for MRM patients, chest wall radiation therapy was given in 2 Gy fractions to mean total dose 50Gy (50-60). For positive axillary nodes, supra-clavicular fields were used and given mean total dose of 45 Gy ( ). All patients were treated using three dimensional conformal radiation therapy (3DCRT) and on multileaf collimator (MLC) assisted linear accelerator. Hormonal therapy was given to 66 patients (8.9%) in the form of tamoxifen (46.4%), letrozole (9.8%) and sequential regimen in 9.8%. Mean duration of hormonal therapy was 5.5 years (range; ). G. J. O. Issue 17, 2015 Figure 1: Cumulative locoregional control in cohort at 5, 10 and 15 years (OS) rates were 74.2% (95% CI: ) and 77.4% (95% CI: ) respectively. Univariate analysis of clinical prognostic factors for LRR in our cohort showed four prognostic factors influencing the LRR: (a) age less than 40 years (HR:4.3, 95% CI: ), (b) Locoregional recurrence, distant control and overall survival A total of 10 locoregional recurrences (8.93%) were seen among 112 breast cancer patients. Four (40%) LRR occurred at scar site and 6 LRR (60%) were seen in ipsilateral axilla and supraclavicular regions. Median time of LRR was 3.6 years (range: ). The actual LRC rates at 10 years were 86.4% (Figure 1). Actual 10 year distant control (DC) and overall survival 11 Table 2: Univariate analysis of clinical prognostic factors for locoregional recurrence in breast cancer patients Abbreviations: CI= confidence interval, BMI= body mass index, BCS= breast conserving surgery, MRM=modified radical mastectomy
8 Impact of BMI on Locoregional Control in Breast Cancer, E.F. Al Saeed, et. al. Table 3: Univariate analysis of histopathological prognostic factors for locoregional recurrence in breast cancer Abbreviations: IDC= infiltrating ductal carcinoma, ILC= invasive lobular carcinoma, LVSI= lymphovascular space invasion, T= primary tumor, N= axillary nodes, CI= confidence interval Table 4. Multivariate analysis of prognostic factors for locoregional recurrence in breast cancer Abbreviations: CI=confidence interval, BMI= body mass index, T= primary tumor size, N= axillary nodal status premenopausal status (HR:3.4, 95% CI: ), (c) BMI below 18.5 kg/m2(hr: 3.2, 95% CI: ) and (d) no adjuvant radiotherapy (HR: 5.2, 95% CI: ) (Table2). Univariate analysis of histopathological prognostic factors for LRR in our cohort showed five prognostic factors influencing the LRR: (a) IDC histological type (HR:2.2, 95% CI: ), (b) stage T4 (HR: 1.8, 95% CI: ), (c) N2 and N3 nodal status (HR:1.8, 95% CI: ), (d) negative ER status (HR:1.2, 95% CI: ) and (e) Her 2neu overexpression (HR:2.1, 95% CI: ) (Table3). In multivariate analysis, age less than 35 years, BMI is below 18.5 kg/m 2, premenopausal status, no adjuvant radiotherapy, T and N stage were still independent important prognostic factors for LRR in our cohort (Table4). 12 Figure 2: Cumulative locoregional control in cohort according to BMI subgroups According to BMI groups, patients with BMIs below 18.5 kg/m 2 followed by overweight (BMI kg/m 2 ) patients had poor LRR in comparison to normal, obese and morbid obese patients (Figure 2).
9 G. J. O. Issue 17, 2015 BMI was not found as prognostic factor for distant control in our cohort. Discussion Breast cancer is the major public health concern in Saudi Arabia as the most common cancer among women with overall percentage of 22.4%. The most common age group found to be affected is years with age-specific incidence of breast cancer of 45 per 100,000 at the age of 45 years (10). Obesity is known as causative factor for the development of breast cancer and is associated with dismal prognosis in breast cancer patients because of delayed diagnosis among overweight women or the growth and spread of breast cancer may be more rapid in obese women and consequently, obese women would tend to have more recurrences (11). In Saudi Arabia 80% of premenopausal women are either overweight or obese which alarms the grave prognosis of breast cancer as compared to other parts of the world (12). However, impact of obesity or increased BMI on locoregional control in breast cancer patients is less studied. Our retrospective data showed two interesting relationships: (a) an inverse association between BMI and LRR and (b) positive relationship between BMI (26-30 kg/m 2 ) and LRR. Then after the risk of LRR markedly reduced in obese (BMI above 31 kg/m 2 ) and morbid obese patients. This could be explained by four hypotheses; (1) Bad clinical and histopathological features in patients with BMI below 18.5 kg/m 2 in our cohort. Thin premenopausal women tend to have more high levels of endogenous estrogen level than obese premenopausal women, which enhances the risk LRR (13). (2) Low sample size of patients with BMI below 18.5 Kg/m 2 (3) Patients below 18.5 kg/m2 have BCS. The relationship between tumor size and breast volume might be another explanation. Women with lower BMI have smaller breast and less adipose tissue which makes it difficult for wide negative margins during lumpectomy (14). (4) In our cohort obese and morbid obese patients had more ER and PR receptors and the use of hormonal therapy is associated with low risk of LRR as compared to overweight patients (15). Strengths of our study were long follow up period and availability of complete data; however our study can be criticized for (a) low sample size especially patient with BMI less than 18.5 kg/m2 and (b) lack of impact of BMI on distant failure which shall be addressed in large prospective trials. In conclusion, underweight patients with breast cancer are more prone for locoregional recurrences as compared to obese and morbid obese patients. For these patients, boost dose to adjuvant radiotherapy can reduce the risk of locoregional failures and this question can be answered more properly in prospective trials on this subject. References 1. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, Al-Marzouki K, Abdullah MA, Al-khadra AH, Al-Harthi SS, Al- Shahid MS, Al-Mobeireek A, Nouh MS. Obesity in Saudi Arabia. Saudi Med Journal 2005;26: Al-Eid HS. Cancer Incidence and Survival Report Saudi Arabia 2007, reports/scr2007.pdf 3. Ursin G, Longnecker MP, Haile RW, et al. A metaanalysis of body mass index and risk of premenopausal breast cancer. Epidemiology 1995;6: Folsom AR, Kaye SA, Prineas RJ, et al. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990;131: A. R. Carmichael, Obesity and Prognosis of Breast Cancer. Obesity Reviews 2006; 7: Donegan WL, Hartz AJ, Rimm AA: The association of body weight with recurrent cancer of the breast. Cancerc1978; 41:
10 Impact of BMI on Locoregional Control in Breast Cancer, E.F. Al Saeed, et. al. 7. Hebert J, Augustine A, Barone J, Kabat G, Kinne D, Winder E: Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int J Cancer 1988; 42: Senie R, Rosen P, Rhodes P, Lesser M, Kinne D: Obesity at diagnosis of breast carcinoma influences duration of disease free survival. Ann Intern Med 1992; 116: Marret H, Perrotin F, Bougnoux P, Descamps P, Hubert B, Lefranc T, Le Floch O, Lansac J, Body G. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat 2001;66: NCR Report. Cancer Incidence Report, National Cancer Registry Willett W, Browne ML, Bain C: Relative weight and risk of breast cancer among pre-menopausal women. Am J Epidemiol 1985;122: Hamilton CJCM, Jaroudi KA, Sieck UV. Highprevalence of obesity in a Saudi infertility population. AnnalsSaudi Medicine 1995; 15: Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous concentrations with menopausal status. J Natl Cancer Inst 1996;88: Waljee JF, Hu ES, Newman LA, Alderman AK. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol 2008;15: Verreault R, Brisson J, Deschenes L, Naud F: Body weight and prognostic indicators in breast cancer modifying effect of estrogen receptors. Am J Epidemiol 1989;129:
The Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationPrediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography
Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman
More informationThe Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationThe Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationThe Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationThe Gulf Journal of Oncology
The Gulf Journal of Oncology ISSUE 17 JANUARY 2015 Table of Contents Original Articles /Studies Impact of BMI on Locoregional Control among Saudi Patients with Breast Cancer after Breast Conserving surgery
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationTime to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationEffects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes
Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationLocoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation
Locoregional Outcomes in Clinical Stage IIB Breast Cancer After Neoadjuvant Therapy and Mastectomy With or Without Radiation Dayssy A. Diaz, MD, Judith Hurley, MD, Isildinha Reis, PhD, Cristiane Takita,
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationLife Science Journal 2014;11(7)
Life Science Journal 4;(7) http://www.lifesciencesite.com Impact of primary tumor resection on response and survival in metastatic breast cancer patients Enas. A. Elkhouly¹, Eman. A. Tawfik ¹, Alaa. A.
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationTata Memorial Centre s opinion is summarized as follows:
February 2 nd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationCHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD ( ) - A RETROSPECTIVE ANALYSIS
Archive of Oncology 2000;8(Suppl 1):7. SESSION 1 CHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD (1995-2000) - A RETROSPECTIVE ANALYSIS 7 Archive of Oncology 2000;8(Suppl 1):8. 8 Extended
More informationWhat is the recommended regimen for adjuvant radiation therapy? Tata Memorial Centre s opinion is summarized as follows:
February 3 rd 2015 Dear Ms., Thank you for reaching out to Tata Memorial Centre for an expert opinion in regard to assessing your treatment options. Navya Network is pleased to offer this online consultation
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationRepeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje
University of Groningen Local treatment in young breast cancer patients Joppe, Enje IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationReal-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study
Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationClinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationRADIOTHERAPY FOR STAGE II AND STAGE III BREAST CANCER PATIENTS WITH NEGATIVE LYMPH NODES AFTER PREOPERATIVE CHEMOTHERAPY AND MASTECTOMY
doi:10.1016/j.ijrobp.2010.12.054 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. e1 e7, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front matter
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationInvasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationAuthor's response to reviews
Author's response to reviews Title: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationBy KAREN HUI LI B.Sc., Brock University, A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE
Micrometastatic Node-Positive Breast Cancer: An Analysis of Survival Outcomes and Prognostic Impact of the Number of Positive Nodes and the Ratio of Positive to Excised Nodes in Comparison to Node-Negative
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationA Study on Importance of Molecular Subtyping As a Prognostic Indicator of Breast Carcinoma
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-8, p-issn: 79-86.Volume 8, Issue Ser. (January. 9), PP - www.iosrjournals.org A Study on Importance of Molecular Subtyping As a Prognostic
More informationCa in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationDelayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
Annals of Oncology 11: 515-519, 2000. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationFactors Affecting Survival of Women Diagnosed with Breast Cancer in El-Minia Governorate, Egypt
IJPM Factors Affecting Survival of Women Diagnosed with Breast Cancer in El-Minia Governorate, Egypt Amany Edward Seedhom 1, Nashwa Nabil Kamal 1 1 MD, Lecturer of Public Health, Department of Public Health,
More information